As you can read below there are two drugs now that have been permitted for use by the FDA. The drug has been tested against other viruses. It has not yet been tested in humans or monkeys yet. Brincidofovir has been under development for 14 years by a company in North Carolina and has been studied for use against smallpox and chickenpox.
The Food and Drug Administration's expanded it’s access program, and the company has been authorized to provide brincidofovir to multiple Ebola patients. BD
The Food and Drug Administration (FDA) on Monday approved the use of an experimental drug that has been hailed as one of the pharmaceutical industry's best chances at fighting the Ebola virus.
Chimerix, a North Carolina-based biopharmaceutical company, announced Monday that it has received approval to administer an antiviral drug called brincidofovir that has successfully treated Ebola in lab tests.
The drug has also been tested by the Centers for Disease Control and Prevention and the National Institutes of Health, though it is not expected to win approval for wide public use until late 2016.
"We are hopeful that brincidofovir may offer a potential treatment for Ebola Virus Disease during this outbreak," the company's president and CEO, M. Michelle Berrey, said in a release.
Another drug that has been used to treat Ebola-infected patients, TKM-Ebola, has also been permitted for emergency use by the FDA.